董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Claudia Grimaldi | 女 | Vice President, Principal Financial Officer, Chief Compliance Officer and Director | 52 | 32.00万美元 | 44.40 | 2023-07-25 |
| James Moran | 男 | Director | 78 | 4.30万美元 | 未持股 | 2023-07-25 |
| Ram Mukunda | 男 | President, Chief Executive Officer and Director | 64 | 132.60万美元 | 266.87 | 2023-07-25 |
| Richard Prins | 男 | Chairman of the Board | 66 | 7.50万美元 | 26.80 | 2023-07-25 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Claudia Grimaldi | 女 | Vice President, Principal Financial Officer, Chief Compliance Officer and Director | 52 | 32.00万美元 | 44.40 | 2023-07-25 |
| Ram Mukunda | 男 | President, Chief Executive Officer and Director | 64 | 132.60万美元 | 266.87 | 2023-07-25 |
董事简历
中英对照 | 中文 | 英文- Claudia Grimaldi
-
副总裁兼首席财务官Claudia Grimaldi负责管理多个国家的会计和财务团队，并负责确保SEC、FINRA、NYSE、IRS、Xetra2等公司及时、准确地遵守法律和法规。她在SEC备案，法规合规和披露方面拥有十多年的经验，曾于2011年5月至2013年担任财务报告和合规经理，随后于2013年至2018年5月担任财务报告和合规总经理。她还担任我们一些子公司的董事/经理。Grimaldi女士以优异成绩毕业于哥伦比亚排名前五的大学Javeriana University，获得心理学文学学士学位。她持有北卡罗来纳州Meredith College的综合管理工商管理硕士学位，以最高荣誉毕业。她是Delta Mu Delta International Honor Society成员。此外，她曾参加the University of Virginia的达顿商学院（Darden School of Business）财务管理高管计划，以及SEC报告和合规研讨会。她还会说流利的英语和西班牙语。
Claudia Grimaldi,Vice-president, PFO, Chief Compliance Officer, and Director is responsible for managing the accounting and finance teams in various countries and is responsible for ensuring timely and accurate statutory and regulatory compliance (SEC, FINRA, NYSE, IRS, XETRA 2, among others). In addition, she is responsible for building and managing an international team of doctors, scientists, and advisors that conduct and manage pre-clinical and FDA registered trials focused on Alzheimer's disease. She is also responsible for relationships with partners that provide, among others, animal studies, cannabinoids, and software for AI. She has more than thirteen (13) years of experience with SEC filings, regulatory compliance, and disclosures, having held increasing responsibilities first as Manager of financial reporting and compliance from May 2011 to 2013 and then as General Manager financial reporting and compliance from 2013 to May 2018. She also serves as a Director/Manager for some of Igc Pharma, Inc. subsidiaries. Ms. Grimaldi graduated summa cum laude from Javeriana University, a top five university in Colombia, with a Bachelor of Arts in Psychology. She holds an MBA in General Management, graduating with Highest Honors, from Meredith College, in North Carolina. She is a member of Delta Mu Delta International Honor Society. She has also completed Executive Education courses on SEC compliance, finance from UVA, and corporate governance from the Columbia Business School. In addition, she has attended the Darden School of Business Financial Management Executives program at the University of Virginia, and SEC reporting and compliance seminars. Currently she is pursuing her Directorship Certification with the National Association of Corporate Directors (NACD). She is also fluent in both English and Spanish. - 副总裁兼首席财务官Claudia Grimaldi负责管理多个国家的会计和财务团队，并负责确保SEC、FINRA、NYSE、IRS、Xetra2等公司及时、准确地遵守法律和法规。她在SEC备案，法规合规和披露方面拥有十多年的经验，曾于2011年5月至2013年担任财务报告和合规经理，随后于2013年至2018年5月担任财务报告和合规总经理。她还担任我们一些子公司的董事/经理。Grimaldi女士以优异成绩毕业于哥伦比亚排名前五的大学Javeriana University，获得心理学文学学士学位。她持有北卡罗来纳州Meredith College的综合管理工商管理硕士学位，以最高荣誉毕业。她是Delta Mu Delta International Honor Society成员。此外，她曾参加the University of Virginia的达顿商学院（Darden School of Business）财务管理高管计划，以及SEC报告和合规研讨会。她还会说流利的英语和西班牙语。
- Claudia Grimaldi,Vice-president, PFO, Chief Compliance Officer, and Director is responsible for managing the accounting and finance teams in various countries and is responsible for ensuring timely and accurate statutory and regulatory compliance (SEC, FINRA, NYSE, IRS, XETRA 2, among others). In addition, she is responsible for building and managing an international team of doctors, scientists, and advisors that conduct and manage pre-clinical and FDA registered trials focused on Alzheimer's disease. She is also responsible for relationships with partners that provide, among others, animal studies, cannabinoids, and software for AI. She has more than thirteen (13) years of experience with SEC filings, regulatory compliance, and disclosures, having held increasing responsibilities first as Manager of financial reporting and compliance from May 2011 to 2013 and then as General Manager financial reporting and compliance from 2013 to May 2018. She also serves as a Director/Manager for some of Igc Pharma, Inc. subsidiaries. Ms. Grimaldi graduated summa cum laude from Javeriana University, a top five university in Colombia, with a Bachelor of Arts in Psychology. She holds an MBA in General Management, graduating with Highest Honors, from Meredith College, in North Carolina. She is a member of Delta Mu Delta International Honor Society. She has also completed Executive Education courses on SEC compliance, finance from UVA, and corporate governance from the Columbia Business School. In addition, she has attended the Darden School of Business Financial Management Executives program at the University of Virginia, and SEC reporting and compliance seminars. Currently she is pursuing her Directorship Certification with the National Association of Corporate Directors (NACD). She is also fluent in both English and Spanish.
- James Moran
-
James Moran，自2022年1月起担任Igc Pharma，Inc.的独立董事。他在弗吉尼亚州第8国会选区服务了24年，在那里他被称为“问题解决者”。在他的整个任期内，他展示了两党的领导力，并在两党之间努力寻找共同立场，以解决复杂的问题。他曾在拨款、银行、财务和预算委员会任职。他在国防、卫生和环境领域发挥了领导作用。在国会任职的24年里，莫兰议员被公认为医疗保健和国家安全、环境保护和可持续性、国际贸易和财政责任等领域创新研发的倡导者。他升任拨款委员会的高级领导，使他得以将数十亿美元带入他在北弗吉尼亚的亚历山大、阿灵顿和费尔法克斯县的社区。在当选公职35年后退休的莫兰议员现在供职于一家大型律师事务所，代表国防、科技、娱乐和国际外交领域的国际和国内客户。他还在几个非盈利基金会担任领导职务，也是政府区块链协会的成员。莫兰议员在匹兹堡大学公共与国际事务研究生院获得公共管理硕士学位，在圣十字学院获得经济学学士学位。
James Moran,has served on the Board as an Independent Director since January 2022. He served on Virginia's 8th Congressional District for 24 years, where he was known as a "Problem Solver." Throughout his tenure, he demonstrated bipartisan leadership and worked across the aisle to find common ground to resolve complex issues. He served on the Appropriation, Banking and Finance and Budget committees. He played a leadership role in the areas of defense, health, and the environment. Having retired after 35 years in elected office, Congressman Moran is now with a major law firm and represents international and domestic clients in the defense, technology, entertainment, and international diplomacy sectors. He also serves in leadership roles for several non-profit foundations and is also a member of the Government Blockchain Association. Congressman Moran received a Master's Degree in Public Administration from the University of Pittsburgh Graduate School of Public and International Affairs and a Bachelors in Economics from the College of the Holy Cross. - James Moran，自2022年1月起担任Igc Pharma，Inc.的独立董事。他在弗吉尼亚州第8国会选区服务了24年，在那里他被称为“问题解决者”。在他的整个任期内，他展示了两党的领导力，并在两党之间努力寻找共同立场，以解决复杂的问题。他曾在拨款、银行、财务和预算委员会任职。他在国防、卫生和环境领域发挥了领导作用。在国会任职的24年里，莫兰议员被公认为医疗保健和国家安全、环境保护和可持续性、国际贸易和财政责任等领域创新研发的倡导者。他升任拨款委员会的高级领导，使他得以将数十亿美元带入他在北弗吉尼亚的亚历山大、阿灵顿和费尔法克斯县的社区。在当选公职35年后退休的莫兰议员现在供职于一家大型律师事务所，代表国防、科技、娱乐和国际外交领域的国际和国内客户。他还在几个非盈利基金会担任领导职务，也是政府区块链协会的成员。莫兰议员在匹兹堡大学公共与国际事务研究生院获得公共管理硕士学位，在圣十字学院获得经济学学士学位。
- James Moran,has served on the Board as an Independent Director since January 2022. He served on Virginia's 8th Congressional District for 24 years, where he was known as a "Problem Solver." Throughout his tenure, he demonstrated bipartisan leadership and worked across the aisle to find common ground to resolve complex issues. He served on the Appropriation, Banking and Finance and Budget committees. He played a leadership role in the areas of defense, health, and the environment. Having retired after 35 years in elected office, Congressman Moran is now with a major law firm and represents international and domestic clients in the defense, technology, entertainment, and international diplomacy sectors. He also serves in leadership roles for several non-profit foundations and is also a member of the Government Blockchain Association. Congressman Moran received a Master's Degree in Public Administration from the University of Pittsburgh Graduate School of Public and International Affairs and a Bachelors in Economics from the College of the Holy Cross.
- Ram Mukunda
-
Ram Mukunda， 2005年4月29日起担任Igc Pharma, Inc.的董事、首席执行官兼总裁。他负责一般管理，在过去的九年里，他主要负责公司在医疗大麻素和制药行业的战略和定位。他一直是公司大部分专利申请的首席发明人和架构师，并推动研发和医学试验，这支持公司带来低成本药物的愿望，解决影响人类的疾病和疾病。加入IGC之前，从1990年1月到2004年5月，他担任Startec Global Communications的创始人兼首席执行官，并于1997年在纳斯达克上市。在加入Startec之前，他曾担任通信卫星服务提供商Intelsat的战略规划顾问，在此之前，他曾在华尔街一家精品公司的债券市场工作。他是the University of Maryland, School of Engineering访问委员会的荣誉成员。从2001年到2003年，他是哈佛大学肯尼迪政府学院、贝尔弗科学与国际事务中心的理事会成员。Mukunda先生是多个奖项的获得者，其中包括2013年马里兰大学年度国际校友奖、2001年杰出工程校友奖、1998年Ernst & Young, LLP年度企业家奖。他持有the University of Maryland的电气工程学士学位、数学学士学位和工程硕士学位。
Ram Mukunda,has served as Director, CEO and President since April 29, 2005. He is responsible for general management and, over the past nine years, has been largely responsible for the Company's strategy and positioning in the medical cannabinoids and pharmaceutical industry. Prior to IGC, from January 1990 to May 2004, Mr. Mukunda served as Founder and CEO of Startec Global Communications, which he took public in 1997 on NASDAQ. Prior to Startec, he served as Strategic Planning Advisor at Intelsat, a communications satellite services provider and prior to that worked in the bond market for a boutique firm on Wall Street. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering. From 2001 to 2003, he was a Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda is the recipient of several awards including, among others, the 2013 University of Maryland's International Alumnus of the year award, the 2001 Distinguished Engineering Alumnus Award, the 1998 Ernst & Young, LLP's Entrepreneur of the Year Award. He holds a B.S. degree in Electrical Engineering, a B.S degree in Mathematics, and a M.S. in Engineering from the University of Maryland. Mr. Mukunda has traveled extensively, and managed companies in Europe and Asia. - Ram Mukunda， 2005年4月29日起担任Igc Pharma, Inc.的董事、首席执行官兼总裁。他负责一般管理，在过去的九年里，他主要负责公司在医疗大麻素和制药行业的战略和定位。他一直是公司大部分专利申请的首席发明人和架构师，并推动研发和医学试验，这支持公司带来低成本药物的愿望，解决影响人类的疾病和疾病。加入IGC之前，从1990年1月到2004年5月，他担任Startec Global Communications的创始人兼首席执行官，并于1997年在纳斯达克上市。在加入Startec之前，他曾担任通信卫星服务提供商Intelsat的战略规划顾问，在此之前，他曾在华尔街一家精品公司的债券市场工作。他是the University of Maryland, School of Engineering访问委员会的荣誉成员。从2001年到2003年，他是哈佛大学肯尼迪政府学院、贝尔弗科学与国际事务中心的理事会成员。Mukunda先生是多个奖项的获得者，其中包括2013年马里兰大学年度国际校友奖、2001年杰出工程校友奖、1998年Ernst & Young, LLP年度企业家奖。他持有the University of Maryland的电气工程学士学位、数学学士学位和工程硕士学位。
- Ram Mukunda,has served as Director, CEO and President since April 29, 2005. He is responsible for general management and, over the past nine years, has been largely responsible for the Company's strategy and positioning in the medical cannabinoids and pharmaceutical industry. Prior to IGC, from January 1990 to May 2004, Mr. Mukunda served as Founder and CEO of Startec Global Communications, which he took public in 1997 on NASDAQ. Prior to Startec, he served as Strategic Planning Advisor at Intelsat, a communications satellite services provider and prior to that worked in the bond market for a boutique firm on Wall Street. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering. From 2001 to 2003, he was a Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda is the recipient of several awards including, among others, the 2013 University of Maryland's International Alumnus of the year award, the 2001 Distinguished Engineering Alumnus Award, the 1998 Ernst & Young, LLP's Entrepreneur of the Year Award. He holds a B.S. degree in Electrical Engineering, a B.S degree in Mathematics, and a M.S. in Engineering from the University of Maryland. Mr. Mukunda has traveled extensively, and managed companies in Europe and Asia.
- Richard Prins
-
Richard Prins自2012年起担任Igc Pharma公司董事长、审计委员会主席和薪酬委员会主席，自2007年5月起担任独立董事。1996年3月至2008年，他担任Ferris, Baker Watts, Incorporated （FBW）的投资银行总监。他曾担任加拿大皇家银行（RBC）的顾问，直到2009年1月。Prins先生目前在另一个董事会任职，在非营利组织advance Native Missions担任全职志愿者，并且是一名私人投资者。2003年2月以来，他一直担任Amphastar Pharmaceuticals, Inc.的董事。他持有Colgate University的学士学位和Oral Roberts University的工商管理硕士学位。
Richard Prins,has been Igc Pharma, Inc. Chairman, Audit Committee and Compensation Committee Chairman since 2012 and has served as an Independent Director since May 2007. Mr. Prins has extensive experience in private equity investing and investment banking. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated (FBW). Mr. Prins served in a consulting role for RBC until January 2009. Mr. Prins currently serves on one other board, volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals, Inc. Mr. Prins holds a B.A. degree from Colgate University and an M.B.A. from Oral Roberts University. Mr. Prins has substantial knowledge and experience with U.S. capital markets, has served on and chaired audit and compensation committees of boards, has extensive experience in finance, accounting, and internal controls over financial reporting. - Richard Prins自2012年起担任Igc Pharma公司董事长、审计委员会主席和薪酬委员会主席，自2007年5月起担任独立董事。1996年3月至2008年，他担任Ferris, Baker Watts, Incorporated （FBW）的投资银行总监。他曾担任加拿大皇家银行（RBC）的顾问，直到2009年1月。Prins先生目前在另一个董事会任职，在非营利组织advance Native Missions担任全职志愿者，并且是一名私人投资者。2003年2月以来，他一直担任Amphastar Pharmaceuticals, Inc.的董事。他持有Colgate University的学士学位和Oral Roberts University的工商管理硕士学位。
- Richard Prins,has been Igc Pharma, Inc. Chairman, Audit Committee and Compensation Committee Chairman since 2012 and has served as an Independent Director since May 2007. Mr. Prins has extensive experience in private equity investing and investment banking. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated (FBW). Mr. Prins served in a consulting role for RBC until January 2009. Mr. Prins currently serves on one other board, volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals, Inc. Mr. Prins holds a B.A. degree from Colgate University and an M.B.A. from Oral Roberts University. Mr. Prins has substantial knowledge and experience with U.S. capital markets, has served on and chaired audit and compensation committees of boards, has extensive experience in finance, accounting, and internal controls over financial reporting.
高管简历
中英对照 | 中文 | 英文- Claudia Grimaldi
副总裁兼首席财务官Claudia Grimaldi负责管理多个国家的会计和财务团队，并负责确保SEC、FINRA、NYSE、IRS、Xetra2等公司及时、准确地遵守法律和法规。她在SEC备案，法规合规和披露方面拥有十多年的经验，曾于2011年5月至2013年担任财务报告和合规经理，随后于2013年至2018年5月担任财务报告和合规总经理。她还担任我们一些子公司的董事/经理。Grimaldi女士以优异成绩毕业于哥伦比亚排名前五的大学Javeriana University，获得心理学文学学士学位。她持有北卡罗来纳州Meredith College的综合管理工商管理硕士学位，以最高荣誉毕业。她是Delta Mu Delta International Honor Society成员。此外，她曾参加the University of Virginia的达顿商学院（Darden School of Business）财务管理高管计划，以及SEC报告和合规研讨会。她还会说流利的英语和西班牙语。
Claudia Grimaldi,Vice-president, PFO, Chief Compliance Officer, and Director is responsible for managing the accounting and finance teams in various countries and is responsible for ensuring timely and accurate statutory and regulatory compliance (SEC, FINRA, NYSE, IRS, XETRA 2, among others). In addition, she is responsible for building and managing an international team of doctors, scientists, and advisors that conduct and manage pre-clinical and FDA registered trials focused on Alzheimer's disease. She is also responsible for relationships with partners that provide, among others, animal studies, cannabinoids, and software for AI. She has more than thirteen (13) years of experience with SEC filings, regulatory compliance, and disclosures, having held increasing responsibilities first as Manager of financial reporting and compliance from May 2011 to 2013 and then as General Manager financial reporting and compliance from 2013 to May 2018. She also serves as a Director/Manager for some of Igc Pharma, Inc. subsidiaries. Ms. Grimaldi graduated summa cum laude from Javeriana University, a top five university in Colombia, with a Bachelor of Arts in Psychology. She holds an MBA in General Management, graduating with Highest Honors, from Meredith College, in North Carolina. She is a member of Delta Mu Delta International Honor Society. She has also completed Executive Education courses on SEC compliance, finance from UVA, and corporate governance from the Columbia Business School. In addition, she has attended the Darden School of Business Financial Management Executives program at the University of Virginia, and SEC reporting and compliance seminars. Currently she is pursuing her Directorship Certification with the National Association of Corporate Directors (NACD). She is also fluent in both English and Spanish.- 副总裁兼首席财务官Claudia Grimaldi负责管理多个国家的会计和财务团队，并负责确保SEC、FINRA、NYSE、IRS、Xetra2等公司及时、准确地遵守法律和法规。她在SEC备案，法规合规和披露方面拥有十多年的经验，曾于2011年5月至2013年担任财务报告和合规经理，随后于2013年至2018年5月担任财务报告和合规总经理。她还担任我们一些子公司的董事/经理。Grimaldi女士以优异成绩毕业于哥伦比亚排名前五的大学Javeriana University，获得心理学文学学士学位。她持有北卡罗来纳州Meredith College的综合管理工商管理硕士学位，以最高荣誉毕业。她是Delta Mu Delta International Honor Society成员。此外，她曾参加the University of Virginia的达顿商学院（Darden School of Business）财务管理高管计划，以及SEC报告和合规研讨会。她还会说流利的英语和西班牙语。
- Claudia Grimaldi,Vice-president, PFO, Chief Compliance Officer, and Director is responsible for managing the accounting and finance teams in various countries and is responsible for ensuring timely and accurate statutory and regulatory compliance (SEC, FINRA, NYSE, IRS, XETRA 2, among others). In addition, she is responsible for building and managing an international team of doctors, scientists, and advisors that conduct and manage pre-clinical and FDA registered trials focused on Alzheimer's disease. She is also responsible for relationships with partners that provide, among others, animal studies, cannabinoids, and software for AI. She has more than thirteen (13) years of experience with SEC filings, regulatory compliance, and disclosures, having held increasing responsibilities first as Manager of financial reporting and compliance from May 2011 to 2013 and then as General Manager financial reporting and compliance from 2013 to May 2018. She also serves as a Director/Manager for some of Igc Pharma, Inc. subsidiaries. Ms. Grimaldi graduated summa cum laude from Javeriana University, a top five university in Colombia, with a Bachelor of Arts in Psychology. She holds an MBA in General Management, graduating with Highest Honors, from Meredith College, in North Carolina. She is a member of Delta Mu Delta International Honor Society. She has also completed Executive Education courses on SEC compliance, finance from UVA, and corporate governance from the Columbia Business School. In addition, she has attended the Darden School of Business Financial Management Executives program at the University of Virginia, and SEC reporting and compliance seminars. Currently she is pursuing her Directorship Certification with the National Association of Corporate Directors (NACD). She is also fluent in both English and Spanish.
- Ram Mukunda
Ram Mukunda， 2005年4月29日起担任Igc Pharma, Inc.的董事、首席执行官兼总裁。他负责一般管理，在过去的九年里，他主要负责公司在医疗大麻素和制药行业的战略和定位。他一直是公司大部分专利申请的首席发明人和架构师，并推动研发和医学试验，这支持公司带来低成本药物的愿望，解决影响人类的疾病和疾病。加入IGC之前，从1990年1月到2004年5月，他担任Startec Global Communications的创始人兼首席执行官，并于1997年在纳斯达克上市。在加入Startec之前，他曾担任通信卫星服务提供商Intelsat的战略规划顾问，在此之前，他曾在华尔街一家精品公司的债券市场工作。他是the University of Maryland, School of Engineering访问委员会的荣誉成员。从2001年到2003年，他是哈佛大学肯尼迪政府学院、贝尔弗科学与国际事务中心的理事会成员。Mukunda先生是多个奖项的获得者，其中包括2013年马里兰大学年度国际校友奖、2001年杰出工程校友奖、1998年Ernst & Young, LLP年度企业家奖。他持有the University of Maryland的电气工程学士学位、数学学士学位和工程硕士学位。
Ram Mukunda,has served as Director, CEO and President since April 29, 2005. He is responsible for general management and, over the past nine years, has been largely responsible for the Company's strategy and positioning in the medical cannabinoids and pharmaceutical industry. Prior to IGC, from January 1990 to May 2004, Mr. Mukunda served as Founder and CEO of Startec Global Communications, which he took public in 1997 on NASDAQ. Prior to Startec, he served as Strategic Planning Advisor at Intelsat, a communications satellite services provider and prior to that worked in the bond market for a boutique firm on Wall Street. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering. From 2001 to 2003, he was a Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda is the recipient of several awards including, among others, the 2013 University of Maryland's International Alumnus of the year award, the 2001 Distinguished Engineering Alumnus Award, the 1998 Ernst & Young, LLP's Entrepreneur of the Year Award. He holds a B.S. degree in Electrical Engineering, a B.S degree in Mathematics, and a M.S. in Engineering from the University of Maryland. Mr. Mukunda has traveled extensively, and managed companies in Europe and Asia.- Ram Mukunda， 2005年4月29日起担任Igc Pharma, Inc.的董事、首席执行官兼总裁。他负责一般管理，在过去的九年里，他主要负责公司在医疗大麻素和制药行业的战略和定位。他一直是公司大部分专利申请的首席发明人和架构师，并推动研发和医学试验，这支持公司带来低成本药物的愿望，解决影响人类的疾病和疾病。加入IGC之前，从1990年1月到2004年5月，他担任Startec Global Communications的创始人兼首席执行官，并于1997年在纳斯达克上市。在加入Startec之前，他曾担任通信卫星服务提供商Intelsat的战略规划顾问，在此之前，他曾在华尔街一家精品公司的债券市场工作。他是the University of Maryland, School of Engineering访问委员会的荣誉成员。从2001年到2003年，他是哈佛大学肯尼迪政府学院、贝尔弗科学与国际事务中心的理事会成员。Mukunda先生是多个奖项的获得者，其中包括2013年马里兰大学年度国际校友奖、2001年杰出工程校友奖、1998年Ernst & Young, LLP年度企业家奖。他持有the University of Maryland的电气工程学士学位、数学学士学位和工程硕士学位。
- Ram Mukunda,has served as Director, CEO and President since April 29, 2005. He is responsible for general management and, over the past nine years, has been largely responsible for the Company's strategy and positioning in the medical cannabinoids and pharmaceutical industry. Prior to IGC, from January 1990 to May 2004, Mr. Mukunda served as Founder and CEO of Startec Global Communications, which he took public in 1997 on NASDAQ. Prior to Startec, he served as Strategic Planning Advisor at Intelsat, a communications satellite services provider and prior to that worked in the bond market for a boutique firm on Wall Street. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering. From 2001 to 2003, he was a Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda is the recipient of several awards including, among others, the 2013 University of Maryland's International Alumnus of the year award, the 2001 Distinguished Engineering Alumnus Award, the 1998 Ernst & Young, LLP's Entrepreneur of the Year Award. He holds a B.S. degree in Electrical Engineering, a B.S degree in Mathematics, and a M.S. in Engineering from the University of Maryland. Mr. Mukunda has traveled extensively, and managed companies in Europe and Asia.